ArticleFrontiers in digital health2026
Interpretable multimodal machine learning for diagnosis of drug-resistant tuberculosis.
Article in Frontiers in digital health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Early detection of drug-resistant tuberculosis (DR-TB) is critical for timely treatment and limiting transmission. Differentiating DR-TB from drug-sensitive TB (DS-TB) remains challenging due to overlapping manifestations and subtle differences in chest X-rays (CXRs). Methods: We developed an explainable multimodal machine learning framework integrating CXR embeddings from a Data-Efficient Image Transformer (DEiT) with patient-level data, including clinical, interpreted radiological, demographic, socioeconomic, and behavioral variables. Using 6,279 subjects from the TB Portals program, model performance was evaluated across three settings comprising CXR embeddings only, patient-level features only, and multimodal. Interpretability was analyzed using Shapley Additive Explanations (SHAP). Results: A multimodal XGBoost model achieved a precision-recall area under the curve (PR-AUC) of 0.9258 and receiver operating characteristic area under the curve (ROC-AUC) of 0.8718. CXR-embeddings-only classifiers performed lower (PR-AUC: 0.8334; ROC-AUC: 0.7369), while patient-level XGBoost yielded highest performance. The multimodal model improved interpretability through complementary structural information. SHAP identified CXR embeddings as primary global drivers. Among patient-level variables, daily contacts and employment status were the strongest contributors, reflecting exposure intensity and socioeconomic conditions. Comorbidity showed moderate effects, while education and case definition had smaller contributions. Key radiological factors included non-tuberculosis abnormalities and mediastinal lymph node involvement, whereas medium-density stabalized fibrotic nodules, medium nodules, and small cavities demonstrated minimal association. Interaction analysis revealed higher risk with increasing comorbidity in the presence of morphological alterations; BMI and age exhibited modest influence. Independent review by two clinicians confirmed plausibility and consistency of SHAP explanations. Discussion: This interpretable multimodal framework supports early DR-TB detection and targeted interventions in high-burden settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.